Journal
ACTA BIOMATERIALIA
Volume 144, Issue -, Pages 279-291Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.actbio.2022.03.026
Keywords
Co-crosslinking; Bioprosthetic heart valve; Poly (ethylene glycol) diacrylate; Hemocompatibility; Cytocompatibility
Funding
- Chengdu Major Science and Tech-nology Innovation Programs [2019-YF08-00235-GX]
- National Natural Science Foundation of China [32071357]
- Sichuan Science and Technology Program [2021YFH0011]
- National Key Research and Development Programs, China [2020YFC1107802]
- Applied Basic Research of Science and Technology Projects of Sichuan Province [2018JY0538]
Ask authors/readers for more resources
A study developed a PEGylation method to modify bioprosthetic heart valves, which exhibited improved antithrombogenicity and cytocompatibility properties compared to traditional crosslinked valves.
With the development of diagnostic techniques, the incidence of bioprosthetic heart valve thrombo-sis (BHVT) is found to be seriously underestimated. Developing bioprosthetic heart valves (BHVs) that have good hemocompatibility without sacrificing other properties such as hydrodynamics and durabil-ity will be an effective strategy to alleviate BHVT. In this study, we developed a PEGylation method by co-crosslinking and subsequent radical polymerization. 2-amino-4-pentenoic acid was used to introduce carbon-carbon double bonds for glutaraldehyde crosslinked pericardia. Then poly (ethylene glycol) di-acrylate (PEGDA) was immobilized on pericardia by radical polymerization. A comprehensive evaluation of the modified pericardia was performed including structural characterization, hemocompatibility, cyto-compatibility, mechanical properties, component stability, hydrodynamic performance and durability of the BHVs. The modified pericardia significantly reduced platelet adhesion by more than 75% compared with traditional glutaraldehyde crosslinked pericardia. Cell viability in the modified pericardia group was nearly 5-fold higher than that in glutaraldehyde crosslinked pericardia. The hydrodynamic performance met the requirements of ISO 5840-3 under physiological aortic valve conditions and its durability was proved after 200 million cycles of accelerated fatigue test. In conclusion, PEGDA modified pericardia ex-hibited improved antithrombogenicity and cytocompatibility properties compared with glutaraldehyde crosslinked pericardia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available